🔎 Trials Near Me

Home › Non-Small Cell Lung Cancer › North Dakota

Non-Small Cell Lung Cancer clinical trials in North Dakota

15 studies for Non-Small Cell Lung Cancer are looking for participants at sites in North Dakota.

Cities in North Dakota

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Sanford Bismarck Medical Center, Bismarck
  • Sanford Broadway Medical Center, Fargo
  • Sanford Roger Maris Cancer Center, Fargo
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT04267848

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

  • Sanford Bismarck Medical Center, Bismarck
  • Sanford Broadway Medical Center, Fargo
  • Sanford Roger Maris Cancer Center, Fargo
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07293247

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

  • Sanford Fargo Medical Center ( Site 3236), Fargo
  • Altru Health System ( Site 3254), Grand Forks
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07513376

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • Sanford Bismarck Medical Center, Bismarck
  • Essentia Health Cancer Center-South University Clinic, Fargo
  • Sanford Broadway Medical Center, Fargo
  • and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06498635

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

  • Sanford Fargo Medical Center ( Site 0039), Fargo
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06731907

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

  • Sanford Roger Maris Cancer Center, Fargo
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Jun 26, 2026 · NCT04614103

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • Sanford Bismarck Medical Center, Bismarck
  • Sanford Broadway Medical Center, Fargo
  • Sanford Roger Maris Cancer Center, Fargo
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 3, 2026 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • Sanford Bismarck Medical Center, Bismarck
  • Sanford Broadway Medical Center, Fargo
  • Sanford Roger Maris Cancer Center, Fargo
RecruitingPhase 2
18 Minutes · All sexes · Updated May 5, 2026 · NCT06031688

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • Sanford Bismarck Medical Center, Bismarck
  • Essentia Health Cancer Center-South University Clinic, Fargo
  • Sanford Broadway Medical Center, Fargo
  • and 1 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated May 5, 2026 · NCT06616584

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • Essentia Health Cancer Center-South University Clinic, Fargo
RecruitingObservational study
Ages 18 and older · All sexes · Updated Mar 17, 2026 · NCT06418204

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Fargo
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.